ResMed Inc. (RMD) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $232.37 (-8.11%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 13, 2026 | Anthony Petrone | Evercore ISI | $255.00 | +9.7% |
| Jan 30, 2026 | Craig Wong-Pan | RBC Capital | $314.00 | +35.1% |
| Jan 30, 2026 | Brett Fishbin | KeyBanc | $302.00 | +30.0% |
| Dec 18, 2025 | Jonathan Block | Stifel Nicolaus | $260.00 | +11.9% |
| Dec 12, 2025 | Marcus Curley | UBS | $345.00 | +48.5% |
| Oct 31, 2025 | Brett Fishbin | KeyBanc | $299.00 | +28.7% |
| Oct 31, 2025 | David Bailey | Morgan Stanley | $305.00 | +31.3% |
| May 20, 2025 | David Bailey | Morgan Stanley | $286.00 | +23.1% |
| Apr 24, 2025 | Brett Fishbin | KeyBanc | $274.00 | +17.9% |
| Apr 16, 2025 | Anthony Petrone | Mizuho Securities | $265.00 | +14.0% |
| Jan 31, 2025 | Adam Maeder | Piper Sandler | $260.00 | +11.9% |
| Dec 12, 2024 | Jonathan Block | Stifel Nicolaus | $250.00 | +7.6% |
| Oct 1, 2024 | Craig Wong-Pan | RBC Capital | $224.00 | -3.6% |
| Sep 23, 2024 | Joe Vruwink | Robert W. Baird | $280.00 | +20.5% |
| Sep 18, 2024 | Mike Polark | Wolfe Research | $180.00 | -22.5% |
| Apr 10, 2024 | Craig Wong-Pan | RBC Capital | $187.00 | -19.5% |
| Apr 1, 2024 | Mike Matson | Stifel Nicolaus | $224.00 | -3.6% |
| Oct 27, 2023 | Suraj Kalia | Oppenheimer | $175.00 | -24.7% |
| Sep 6, 2023 | Mike Matson | Needham | $180.00 | -22.5% |
| Jun 20, 2022 | Craig Wong-Pan | RBC Capital | $244.00 | +5.0% |
Top Analysts Covering RMD
RMD vs Sector & Market
| Metric | RMD | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.25 | 2.41 |
| Analyst Count | 16 | 8 | 19 |
| Target Upside | +6.3% | +153002.0% | +21.5% |
| P/E Ratio | 22.47 | 3.45 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.51B | $1.52B | $1.55B | 5 |
| 2027-03-31 | $1.50B | $1.52B | $1.54B | 5 |
| 2027-06-30 | $1.55B | $1.56B | $1.59B | 6 |
| 2028-06-30 | $6.48B | $6.48B | $6.48B | 20 |
| 2029-06-30 | $6.89B | $6.96B | $7.03B | 10 |
| 2030-06-30 | $7.70B | $7.78B | $7.87B | 10 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3.06 | $3.09 | $3.16 | 6 |
| 2027-03-31 | $3.02 | $3.05 | $3.12 | 3 |
| 2027-06-30 | $3.12 | $3.15 | $3.22 | 5 |
| 2028-06-30 | $12.11 | $13.42 | $14.28 | 9 |
| 2029-06-30 | $14.12 | $14.31 | $14.51 | 3 |
| 2030-06-30 | $15.99 | $16.20 | $16.42 | 4 |
Frequently Asked Questions
What is the analyst consensus for RMD?
The consensus among 16 analysts covering ResMed Inc. (RMD) is Buy with an average price target of $242.70.
What is the highest price target for RMD?
The highest price target for RMD is $345.00, set by Marcus Curley at UBS on 2025-12-12.
What is the lowest price target for RMD?
The lowest price target for RMD is $175.00, set by Suraj Kalia at Oppenheimer on 2023-10-27.
How many analysts cover RMD?
16 analysts have issued ratings for ResMed Inc. in the past 12 months.
Is RMD a buy or sell right now?
Based on 16 analyst ratings, RMD has a consensus rating of Buy (2.50/5) with a +6.3% upside to the consensus target of $242.70.
What are the earnings estimates for RMD?
Analysts estimate RMD will report EPS of $3.09 for the period ending 2026-12-31, with revenue estimated at $1.52B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.